PMID: 7545214Apr 1, 1995Paper

Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha

Journal of Medical Virology
M PardoV Carreño

Abstract

Interferon therapy in cirrhotic patients with hepatitis C virus infection is not efficient. In an attempt to improve the response rate, a pilot study using recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone, and in combination with recombinant interferon-alpha (rIFN), was carried out. Fifteen cirrhotic patients with hepatitis C virus infection were randomly allocated into 3 groups to receive treatment: 0.5, 1, or 1.5 micrograms/kg of rhG-CSF daily for 4 weeks, followed by a 4 week resting period, and by the same dose of rhG-CSF daily, plus 6 MU of rIFN 3 times weekly for 4 weeks. They then continued to receive 6 MU of rIFN alone for 4 weeks, followed by 3 MU of rIFN for 16 weeks. After the 4 weeks of treatment with rhG-CSF alone, no changes in alanine aminotransferase (ALT) levels were observed. No changes occurred during the resting period. Three of 10 patients who ended the rhG-CSF plus rIFN treatment period had normal ALT values. During the treatment with rIFN alone, two responders suffered a relapse. The other responder had normal ALT until the first month of follow-up. In summary, the combination of rhG-CSF and rIFN seems promising for the treatment of patients with chronic hepatitis C and liver cirrho...Continue Reading

References

Aug 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K YoshiokaT Morishima
Jul 2, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess
Feb 1, 1992·Seminars in Oncology Nursing·S C McMillan
Feb 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F Sáez-RoyuelaV Carreño
May 18, 1989·The New England Journal of Medicine·W P HammondD C Dale
Nov 30, 1989·The New England Journal of Medicine·G L DavisUNKNOWN Hepatitis Interventional Therapy Group
Nov 30, 1989·The New England Journal of Medicine·A M Di BisceglieJ H Hoofnagle
Dec 18, 1986·The New England Journal of Medicine·J H HoofnagleE A Jones
Jan 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P MarcellinC Bréchot
Oct 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J MartinV Carreño

❮ Previous
Next ❯

Citations

Apr 25, 2000·Journal of Clinical Gastroenterology·C ZavagliaG Pinzello
May 17, 2008·Gastroentérologie Clinique Et Biologique·M Bourliere
Jul 1, 1996·Baillière's Clinical Gastroenterology·G M Dusheiko
Apr 16, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·V Carreño
Jun 10, 2000·Journal of Viral Hepatitis·L A KondiliA Mele
Oct 13, 2006·The American Journal of Gastroenterology·UNKNOWN Department of Veterans Affairs Hepatitis C Resource CenterTeresa L Wright
Mar 20, 1998·Annals of Emergency Medicine·T A Morton, G D Kelen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.